News and Comments

Nektar Therapeutics: Crossing the Barriers and Sailing into the Future

  Tuesday, September 06, 2016

Filled with high hopes and great enthusiasm, we are following up on Nektar’s (NKTR) immunotherapy product NKTR-214, which is in trials by Mayo Clinic and MD Anderson cancer center. The product is a CD122-biased agonist designed to stimulate the patient's own immune system to kill tumor cells. The technology behind the molecule “targeted polymer conjugate technology” has been validated time and time again in clinical trials and in approved drugs marketed by Nektar partners mainly large pharmaceutical firms.  NKTR-214 uses Nektar's this technology to enable preferential activation of immunostimulatory IL-2 receptors. It is a novel mechanism of action in immunotherapy, which is what is attracting us to the drug, knowing in fact that existing IL-2 therapy activates both immunosuppressive as well as immune-stimulatory receptors, which has limited its utility in clinical settings before the surfacing of NKTR-214. More...

Nectar Therapeutics and Seattle Genetics at the AACR Meeting

  Tuesday, April 19, 2016

Meaningful Presentations  More...

OUR REASONS DIFFER INVESTING IN NKTR

  Monday, August 04, 2014

What’s In the Agenda? Technically-oriented analysts sometimes boost small development-stage stocks on news that are not what we meant to hear when we picked these firms to invest in. Although we appreciate the rallying of stocks for whatever reasons, our choice of firms for investment purpose  is based primarily on their validated far-reaching technologies; their pipeline promising products and the professionalism of their management teams.     More...


Recent Postings


Archive


Tags

Multiple Myeloma SYNTA (SNTA) Amgen (AMGN) Sanofi (SNA) Anacor (ANAC) GlaxoSmithKline (GSK) RenenxBio (RGNX) MODERNA HALOZYME (HALO) Tysabri Prolor Biotech (PBTH) Sequenom (SQNM) Ridaforolimus Sangamo (SGMO) Rapamune Bellicum (BLCM) ACADIA (ACAD) Adaptimmune (ADAP) Idenix (IDIX) Pluristem (PSTI) Array Pharmaceuticals (ARRY) ZALTRAP™ Galena (GALE) Ziofpharm (ZIOP) Vertex (VRTX) INNOVIVA (INVA) Mirati Therapeutics (MRTX) Intermune (ITMN) GUARDIAN HEALTH ARCA (ABIO) Elan (ELN) Anadys (ANDS) Biocryst (BCRX) Agenus (AGEN) Merck (MRK) Aimmune Therapeutics (AIMT) galapagos (GLPG) Incyte (INCY) Sarepta (SRPT) Ionis (IONS) Roche (RHHBY) OSI (OSIP) Intrexon (XON) Alder Biopharmaceuticals (ALDR) Micromet (MITI) NOVOCURE (NVCR) Abbott Laboratories (ABT) Spike Therapeutics (ONCE) ADVENTRIX (ANX) Inovio (INO) Cytokinetics (CYTK) Onyx (ONXX) KERYX (KERX) Revlimid (lenolidamide) Dynavax (DVAX) Vitae Pharmaceuticals (VTAE) Sanofi-Aventis (SAN) Genentech Seattle Genetics (SGEN) JUNO (JUNO) Theravance Bio Pharma (TBPH) ISIS (ISIS) REGULUS (RGLS) NEKTAR (NKTR)) Auspex (ASPX) VANDA (VNDA) Velcade (bortezomib) Zerenex SERES THERAPEUTICS (MCRB) Telaprevir Human Genome Sciences (HGSI) KITE (KITE) Roche (ROCHE) CompuGen (CGEN) Editas (EDIT) Jazz Pharmaceuticals (JAZZ) Illumina (ILMN) Endometrial Cancer AGOS (ARGS) Sanofi (SNY) NANTKWEST (NK) ABBVIE (ABBV) Biogen Idec (BIIB) Intercept (ICPT) Dendreon (DNDN) Human Longevity (HLI) Prosensa (RNA) Bristol-Myers Squibb (BMY) C4 Therapeutics Agenus (AGEN ImmunoGen (IMGN) Regeneron (REGN) Trastuzumab-DM1 BIOMARIN (BMRN) Global Cell Therapeutics (GBT) Benlysta (belimumab) Advaxis (ADXS) TOKAI (TKAOI) IDERA (IDRA) CRISPR Therapeutics (CRSP) Ariad (ARIA) PTC Therapeutics (PTCT) Exelixis (EXEL) Alnylam (ALNY) AstraZeneca (AZN) Theravance (THRX) Gilead (GILD) Xoma (XOMA) AERIE PHARMACEUTICALS Herceptin Valeant Pharmaceuticals International (VRX) ARGOS (ARGS) SUNESIS PHARMACEUTICALS (SNSS)